GRAIL Q2 Revenue Jumps 26%, Galleri Volume Surges 35% as FDA Panel Looms
GRAL has more than doubled off its 52-week low of $29.95.
Summary
GRAIL delivered strong Q2 results with total revenue up 26% to $44.7M, driven by a 35% surge in Galleri test volume to over 61,000. Galleri revenue grew 24% to $42.6M, and first-half volume is up 42% year-over-year. Net loss improved slightly to $110.2M, and the company ended the quarter with $861.6M in cash. The completed $110M equity financing with Samsung adds to the balance sheet. Management highlighted upcoming FDA advisory committee in the fall, a key regulatory milestone. This follows positive NHS-Galleri and PATHFINDER 2 data presented at ASCO, reinforcing clinical validation. The combination of accelerating commercial traction and a near-term FDA catalyst makes this a material update for traders.
Updates
· SEC 10-Q — The 10-Q shows Q2 net loss of $110.2M, cash and marketable securities of $861.6M, and 1,570,308 shares issued to Samsung under the stock purchase agreement.
At the time of this announcement, GRAL was trading at $68.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.2B. The 52-week trading range was $29.95 to $118.84. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.